Oxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines. The Company's clinical pipeline is targeting Parkinson's disease, selected cancers and a number of serious eye diseases. The Company has four clinical programs in active development and two other products, including EncorStat and OXB-102, being readied for Phase I/II. EncorStat is being studied for the prevention of corneal graft rejection. OXB-102 is being studied to target Parkinson's disease.